3-(pyridin-2-ylsulfanyl)-1-propanol | 347194-01-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-(pyridin-2-ylsulfanyl)-1-propanol
• 英文别名: 3-(2-pyridylsulfanyl)-1-propanol；3-(Pyridin-2-ylsulfanyl)propan-1-OL；3-pyridin-2-ylsulfanylpropan-1-ol
• CAS: 347194-01-8
• 化学式: C₈H₁₁NOS
• mdl: MFCD12187012
• 分子量: 169.247
• InChiKey: PEGJUTOPVJLXFZ-UHFFFAOYSA-N

物化性质

• 沸点：
  323.1±22.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  58.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(pyridin-2-ylsulfanyl)-1-propanol 在 titanium(IV) isopropylate 、 叔丁基过氧化氢 、 3,3'-bis(7-tert-butyl-8-hydroxyquinolin-2-yl)-1,1'-binaphthyl-2,2'-diol 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 16.0h， 以78%的产率得到
  参考文献：
  名称：

  Design of a New Bimetallic Catalyst for Asymmetric Epoxidation and Sulfoxidation

  摘要：

  A new chiral tethered 8-quinolinol-based ligand class is developed. The binuclear titanium complex of the ligand operates through a novel mechanism allowing for the regio- and stereoselective epoxidation of primary and tertiary homoallylic alcohols (up to 98% ee), as well as first examples of 2-allylic phenols (up to 92% ee). The new catalyst system also promotes the asymmetric oxidation of gamma-hydroxypropyl sulfides giving an important class of chiral sulfoxides that have been inaccessible to date (up to 95% ee).

  DOI：

  10.1021/jacs.5b11429

文献信息

• Quinoline and quinazoline derivatives and drugs containing the same
  申请人：——

  公开号：US20040132727A1

  公开（公告）日：2004-07-08

  There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: 1 wherein R 1 and R 2 represent hydrogen, alkyl or the like; R 3 , R 4 , R 5 and R 6 represent hydrogen, halogen, alkyl, alkoxy or the like; R 11 and R 12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R 3 , R 4 , R 5 and R 6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R 19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.

  提供了一些化合物，可用于治疗由PDGF受体自磷酸化介导的疾病，特别是可抑制新内膜形成肥大的化合物。这些化合物由式（I）或其药理学上可接受的盐或溶剂表示：1其中R1和R2表示氢，烷基或类似物；R3、R4、R5和R6表示氢，卤素，烷基，烷氧基或类似物；R11和R12表示氢，烷基，烷基羰基或类似物；而A表示公式（i）到（x）中的任意一个，但其中R3、R4、R5和R6表示氢，A表示组（v）其中u为0（零）且R19表示苯基，可选地被卤素，烷基或烷氧基取代的化合物被排除。
• Biomacromolecule Polymer Conjugates
  申请人：Maynard D. Heather

  公开号：US20070276088A1

  公开（公告）日：2007-11-29

  Chemical polymerization procedures initiated by, and proceeding from, a biomolecule, particularly a protein, for the formation of biomolecule-polymer conjugates, particularly protein-polymer conjugates, which have therapeutic uses, are intermediates for forming other materials or are usable in diagnostic sensors are disclosed. Polymerization can be initiated by a protein in the absence of additional initiation agents to form the protein-polymer conjugate. Alternatively, polymerization is initiated in the presence of an additional initiation agent that does not interact with the protein. Amino acids existing in the protein can serve as the sites for initiation of the polymerization or the protein can be modified to contain site(s) for initiation or protein with active sites can be prepared by recombinant methods, chemical ligation, solid-phase synthesis, or other techniques to generate site(s) for initiation.

  本发明揭示了由生物分子，特别是蛋白质，引发和进行的化学聚合程序，用于形成生物分子-聚合物共轭物，特别是蛋白质-聚合物共轭物，这些共轭物具有治疗用途，是形成其他材料的中间体或可用于诊断传感器。聚合可以在无需额外引发剂的情况下由蛋白质引发，形成蛋白质-聚合物共轭物。或者，在引发剂存在的情况下，可以引发聚合，该引发剂不与蛋白质相互作用。蛋白质中存在的氨基酸可以作为聚合的起始位点，或者可以修改蛋白质以包含起始位点，或者可以通过重组方法、化学连接、固相合成或其他技术制备具有活性位点的蛋白质，以生成起始位点。
• Multi-Functional Nano-Device
  申请人：McCarthy Patrick

  公开号：US20110286935A1

  公开（公告）日：2011-11-24

  A universal drug delivery platform for monoclonal antibody-based therapeutics is described. This universal platform resolves the problems of immunogenic response associated with the present monoclonal antibody based therapeutics by providing a multifunctional nano-device which comprises a well defined core/shell nano-structure that can function as a drug delivery platform linked to a monoclonal antibody through a single linking group.

  本文描述了一种单克隆抗体治疗的通用药物传递平台。这个通用平台通过提供一个多功能纳米器件来解决目前单克隆抗体治疗所涉及的免疫原性反应问题，该纳米器件包括一个明确定义的核/壳纳米结构，可以通过单个连接基团连接到单克隆抗体，作为药物传递平台。
• QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1243582A1

  公开（公告）日：2002-09-25

  There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: wherein R1 and R2 represent hydrogen, alkyl or the like; R3, R4, R5, and R6 represent hydrogen, halogen, alkyl, alkoxy or the like; R11 and R12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R3, R4, R5 and R6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.

  提供了可用于治疗由 PDGF 受体自身磷酸化介导的疾病的化合物，特别是可抑制新内膜形成肥厚的化合物。这些化合物是式 (I) 所代表的化合物或其药理学上可接受的盐或溶液： 其中 R1 和 R2 代表氢、烷基或类似物；R3、R4、R5 和 R6 代表氢、卤素、烷基、烷氧基或类似物；R11 和 R12 代表氢、烷基、烷基羰基或类似物；A 代表式(i)至(x)中的任意一种，但不包括 R3、R4、R5 和 R6 代表氢且 A 代表基团(v)（其中 u 为 0（零）且 R19 代表任选被卤素、烷基或烷氧基取代的苯基）的化合物。
• EP1243582
  申请人：——

  公开号：——

  公开（公告）日：——